Why Higher Technology Spend Doesn’t Always Equate To More Overall Value
Pharmaceutical companies invest heavily in CRM to improve customer engagement, field productivity, and commercial visibility. But the license fee is only one part of the equation. CRM complexity in pharma can create another cost that is harder to measure: the time commercial teams spend working around the system.
The real cost of CRM can span implementation, systems integration, consulting, change management, training, ongoing support and internal resources. These costs may involve several vendors and sit across different budgets, making it difficult to see the true cost of supporting the CRM environment.
When representatives move between applications, enter the same information more than once, or search across disconnected sources, CRM complexity starts affecting commercial productivity.
Deloitte’s 2026 research found that biopharma sales representatives spend roughly two-thirds of their workday on activities such as researching customers, reviewing products and prescribing trends, scheduling meetings, and completing administrative tasks. Not all of this time is caused by CRM, but it shows how valuable every reduction in operational friction can be.
What does it really cost to implement, operate, support and use our CRM and what commercial value does that investment create?
| Cost area | What it can include |
|---|---|
| Technology | Licenses, platforms, integrations and infrastructure |
| Implementation | Configuration, migration, deployment and consulting |
| Change & Adoption | Training, change management and user support |
| Ongoing Operations | Administration, maintenance, customization and internal resources |
| Commercial Productivity | Time spent navigating systems, entering data and searching for information |
The full cost of CRM is therefore broader than the software itself. A CRM system can become significantly more expensive when complexity creates ongoing operational work for the organization.
The cost rarely appears on the original CRM proposal. It shows up later through additional training, support, duplicated work, slower decisions, and lower adoption.
McKinsey’s recent work on the biopharma operating model points to a broader challenge: organizations need to simplify processes, reduce low-value work and make decisions faster as technology and data become more central to commercial operations. For commercial teams, simplicity does not mean having fewer capabilities. It means making the capabilities easier to use.
Why More Data Doesn’t Always Translate into Better Pharma CRM Performance
Pharma organizations now have access to more commercial information than ever.
A modern pharma CRM may need to connect:
- HCP and customer data
- Prescribing and market trends
- Engagement history
- Territory and account information
- Commercial analytics
- AI-generated insights
The challenge is making those sources work together.
EY’s research report on commercial transformation in pharma highlights the need for more connected data, technology and AI environments rather than fragmented capabilities operating independently. For a field representative, the difference is practical. Having access to several sources of information is not necessarily valuable if the representative still must find the right information, connect the pieces, and decide what matters before customer interactions. Technology should do more of that work in the background.
Ultimately, the cost of a CRM is more than a software subscription. It is the combined cost of licenses, implementation and consulting, change management and support, internal resources—and the time commercial teams spend operating the system.
If that investment adds complexity without giving representatives more time, better information or better customer interactions, then the organization may be paying not only for the technology, but also for the productivity it was supposed to create.
What Should a Simpler Pharma CRM Do?
A simpler pharma CRM should make it easier to:
- Access relevant HCP information
- Understand territory priorities
- Connect commercial data sources
- Apply analytics and AI within the workflow
- Support compliant engagement
- Act on relevant commercial signals
The question is how those capabilities reach the people using them.
A representative should be able to access relevant HCP information without constantly switching between applications. A manager should be able to understand territory priorities without manually consolidating several reports.
And when AI identifies and shows an important commercial signal, that insight should appear close to the workflow where the decision needs to be made.
This is one of the principles behind Close-Up CRM.
Built specifically for life sciences, Close-Up combines CRM, commercial intelligence, analytics, AI, data integration and engagement capabilities in a pharma-focused environment.
Explore the Close-Up CRM Suite
The approach is also supported by decades of experience in the industry. Close-Up currently supports 650+ life sciences organizations, 47,000+ users and operations in more than 50 countries. That experience matters. Simplifying pharma technology requires an understanding of how commercial teams work, not just an extensive list of software capabilities.
How Pharma CRM Turns Data Into Commercial Action
Data integration is a good example. Pharmaceutical organizations often rely on multiple commercial data sources. The challenge is not simply accessing them. It is making them useful when a decision needs to be made. Close-Up CRM can integrate different data sources into the commercial workflow, helping teams work with a more complete view of customers, territories, and market signals.
The Hypera Pharma case gives a practical example. Close-Up’s predictive CRM intelligence was used to identify stockout risks and prioritize field visits across more than 90,000 retail locations.
According to the published case study, the solution contributed to an approximately 75% reduction in average visit time per store, alongside a 4.5% increase in stockout resolution rate during the reported comparison period.
Read the Hypera Pharma case study
The broader lesson is important: data creates more value when commercial teams can act on it without adding another layer of operational work.
How AI Can Reduce CRM Complexity in Pharma
The same principle applies to AI. As pharmaceutical organizations adopt generative and agentic AI, adding another chatbot or standalone application does not automatically simplify the commercial workflow.
The more useful approach is to bring intelligence closer to the systems and processes teams already use.
Close-Up’s AI capabilities support commercial activities such as HCP prioritization, territory intelligence and Suggested Activities. Xplora AI extends this approach by orchestrating specialized AI capabilities around different commercial responsibilities and workflows.
The objective is not to give users another system to manage. It is to reduce the distance between information, insights and action.
How to Measure Pharma CRM ROI Beyond the License
CRM evaluations traditionally focus on license cost, functionality, implementation, and scalability. Those metrics still matter. But commercial leaders should also consider what happens after deployment.
- How much administrative time does the platform require?
- How many systems does a field user need to navigate?
- How easily can new data sources be incorporated?
- How quickly can a new workflow be adopted?
- And how much time does technology give back to commercial teams?
These questions reveal another dimension of CRM ROI: the cost of complexity itself.
A platform with a lower initial price can become expensive if it creates significant operational friction. Conversely, a sophisticated platform can generate stronger value when its complexity remains largely behind the scenes.
Making Pharma CRM Easier for Commercial Teams to Use
For pharma organizations, reducing CRM complexity does not mean choosing less technology. It means making technology work better for people using it.
That can translate into less administrative work, faster access to relevant information, easier adoption of new workflows and better visibility for managers. Over time, these improvements can give commercial teams more capacity to focus on customers and decisions.
Close-Up brings decades of life sciences experience together with pharma-focused CRM, commercial intelligence, data integration, analytics and AI. The platform is already being used at scale by life sciences organizations globally. The next challenge is helping those organizations make increasingly complex commercial environments easier to use.
The Future of Pharma CRM: Less Complexity, More Value
The future of pharma CRM will likely not belong to the platform with the longest feature list. It will be CRM platforms that can connect the capabilities organizations need while keeping the everyday experience simple for the people who use them.
Close-Up CRM is designed around that principle: connect the information, simplify the workflow and help teams act on what matters.
If your organization is evaluating its current CRM environment, considering migration, or looking for a more efficient way to connect commercial data and execution, see what the approach could look like in practice.